 Jutta Sayles URA Rx Group, Inc. President & CEO Visit Website |
Ms. Sayles has been President of URA Rx Group, Inc. for the past 20 years, recently assuming the additional role of CEO.
During this time, Ms. Sayles has taken a small group of healthcare professionals and created a highly motivated team designing and implementing brand-specific strategies for oncology patient management. Under her leadership, URA Rx has been successful in turning compliance support into a competitive advantage for pharmaceutical brands. Spanning the landscape of oncology, from IV to injectable to oral chemotherapies, URA Rx medical professionals address the needs of the individual patient throughout the length of therapy.
URA Rx. Has been recognized for their award-winning programs as well as being published at the National Congress for the ONS.
|
Oncology Q&A
-
What are the rates of noncompliance among patients with different types of cancer? For example, are patients with breast cancer more or less compliant than patients with non-Hodgkin’s disease or lung cancer? Or are noncompliance rates typically equal among all cancer patients, no matter what type?Answered May 4th, 2010 by Expert:At URA Rx, we work with oncology patients across all indications. Non-adherence with prescribed regimens is a problem common to all cancers and all ages, ranging from adolescents being treated for leukemia to older adults undergoing treatment for a variety of cancers. There are more reports in the literature on non-adherence to breast cancer than other types of cancer, but that is likely due to the high incidence of breast cancer and the large number of oral regimens used to treat this common cancer. When we at URA RX look at adherence studies across disease types, the rates of non-adherence range from 0% to 80%. One issue that contributes to increased non-adherence over time is the increased number of maintenance, or long-term treatment regimens. Long-term regimens have been common in breast cancer but are increasingly used in other diseases such as lung and colorectal cancer. Better treatments and supportive care mean patients with metastatic disease are living longer and staying on treatment for extended periods of time. The longer a patient is on therapy, the more likely (s)he is to begin to alter the dosing schedule or to self-modify oral doses to manage unpleasant side effects or to save money.
2 comments2 responses to to “What are the rates of noncompliance among patients with different types of cancer? For example, are patients with breast cancer more or less compliant than patients with non-Hodgkin’s disease or lung cancer? Or are noncompliance rates typically equal among all cancer patients, no matter what type?”
-
Among pharma marketers there is acute awareness re: adherance problems with prescriptions in general and anti-cancer products in particular. The big question here also is – what can we do about it?
Are there any good and credible programs to help increase compliance?
Dilip Phadnis
-
Dear Dilip,
There are many credible patient-adherence program available, many of them are driven by insurance providers and patient support groups, however there are many responsible Pharma companies who have enlisted third parties to provide these services. Take a look at our website http://www.urainc.com and click on case studies for some information regarding such programs.
Thanks for your comment!
Leave a reply
-
